Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Releases Earnings Results, Beats Expectations By $0.16 EPS

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) issued its quarterly earnings data on Tuesday. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.16, Zacks reports. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.71%.

Here are the key takeaways from Fresenius Medical Care AG & Co. KGaA’s conference call:

• Fresenius Medical Care reported an exceptional Q4 and full-year 2025, with Q4 organic revenue growth of 8%, adjusted operating income up 53%, Q4 margin of 13.9% and EPS growth of 68%, hitting the upper end of its 2025 outlook.
• The company generated strong cash flow (EUR 2.7bn in 2025), accelerated its EUR 1bn share buyback (repurchasing ~EUR 586m in 2025 plus additional tranches), raised the dividend and reduced net leverage to 2.5x.
• Under the new FME Reignite strategy Fresenius carved out Value Based Care and began a large-scale U.S. rollout of the 5008X machine (targeting ~20% of owned clinics in 2026, training >7,200 staff and transitioning ~36,000 patients); management calls this a long‑term growth and outcome driver but expects rollout-related OpEx headwinds in 2026.
• Value Based Care is now a separate segment that generated >EUR 2bn revenue in 2025 and reached break‑even for the year (Q4 operating income of EUR 29m), a material improvement from prior loss-making years.
• Management warned of near-term regulatory and phasing headwinds into 2026: strong 2025 tailwinds from TDAPA/phosphate binder and catheter-related payments (around EUR 220m + ~EUR 90m) will partly phase out, and China procurement/regulatory pressures imply a EUR 150–200m regulatory headwind for 2026 and a group margin outlook of 10.5%–12%.

Fresenius Medical Care AG & Co. KGaA Stock Performance

NYSE:FMS opened at $22.70 on Thursday. The stock has a market capitalization of $13.16 billion, a P/E ratio of 11.88, a PEG ratio of 0.72 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The company has a 50 day moving average price of $23.30 and a 200 day moving average price of $24.46.

Fresenius Medical Care AG & Co. KGaA News Roundup

Here are the key news stories impacting Fresenius Medical Care AG & Co. KGaA this week:

• Positive Sentiment: Q4 earnings and revenue materially beat expectations, EPS and margins expanded (driven by FME25+ cost savings), supporting improved profitability and investor confidence. Article Title
• Positive Sentiment: Company reported strong full‑year 2025 results: ~27% earnings growth, operating income at the top end of outlook, reported net income and EPS up sharply, and an accelerated share‑buyback program plus a planned dividend increase — all supportive of future EPS and capital return. Article Title
• Positive Sentiment: Short interest fell sharply in February (down ~20.6% month over month to ~1.85M shares), lowering near‑term bearish pressure and reducing the potential for short‑squeeze volatility.
• Neutral Sentiment: Management updated FY‑2026 guidance with higher revenue targets (company cited ~$23.8B vs. consensus ~$22.6B), but the outlook commentary contained caveats about headwinds; investors will focus on detailed guidance and margins. Article Title
• Neutral Sentiment: Full Q4 earnings call transcript and presentation are available for details on regional performance, reimbursement assumptions and timing of cost savings — useful for investors assessing sustainability of margin gains. Earnings Call Transcript Presentation
• Negative Sentiment: Despite strong headline numbers, the stock reacted negatively to a cautious tone on the outlook and weaker U.S. operational performance; media reported share declines after management commentary. Article Title
• Negative Sentiment: Analyst/commentary pieces highlighted the drop in the share price (one article quantified a ~6.7% decline) and pointed to investor concerns around U.S. growth and the sustainability of margin improvements. Article Title

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the period. Arax Advisory Partners boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $58,000. Finally, Group One Trading LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the 3rd quarter worth about $74,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

FMS has been the topic of several analyst reports. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Weiss Ratings downgraded Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Five research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $28.00.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.